학술논문

His bundle pacing in a patient with atrioventricular conduction abnormalities, persistent atrial flutter at high thromboembolic and bleeding risk after hybrid coronary revascularization and left atrial appendage closure - case report
Document Type
Academic Journal
Source
Bulgarian Cardiology. December 31, 2023 Issue 4, p82, 7 p.
Subject
Coronary artery bypass
Coronary heart disease -- Risk factors
Ischemia -- Risk factors
Arrhythmia -- Risk factors
Clopidogrel
Transluminal angioplasty
Language
English
ISSN
1310-7488
Abstract
Abstract We present a case of a 78-year-old patient with persistent atrial ï¬ utter, history of atrial ï¬ brillation and atrioventricular conduction disturbances, including ï¬ rst-degree atrioventricular block (AVB) and paroxysmal complete AVB. Echocardiography revealed mildly reduced left ventricular ejection fraction (LVEF, 44%). The patient had high thromboembolic risk, had previous ischemic stroke, suffered from chronic coronary artery disease treated with hybrid coronary revascularization (minimally invasive direct coronary artery bypass grafting and subsequent percutaneous coronary intervention) as well as left atrial appendage closure. Because of high bleeding risk, double antiplatelet therapy (acetylsalicylic acid and clopidogrel) combined with low dose of low-molecular-weight heparin after cardiac surgery were introduced. Due to persistent atrial ï¬ utter, complete AVB, lack of intraventricular conduction abnormalities, mildly reduced LVEF and expected high right ventricle pacing burden, the patient was referred for dual-chamber pacemaker implantation using conduction system pacing (CSP), preferentially His bundle pacing (HBP). The procedure was performed with good outcome and CSP was utilized via HBP. After reassessment of thromboembolic and bleeding risk, the patient was discharged home on reduced dose of dabigatran. Short-term follow-up showed stable HBP parameters along with no additional symptoms. Despite good short-term outcomes and no complications in studied patient, large randomized controlled trials are needed to verify long-term safety and efï¬ cacy of HBP to optimize clinical care of patients with atrioventricular conduction abnormalities using a personalized approach.
Author(s): M Szotek (corresponding author) [1]; W. Kula [2]; A. Malik [2]; A. Czunko [1]; J. Lelakowski [1,2]; V. Traykov [3]; P. Matusik [1,2] Author Note(s): Corresponding author: M Szotek [...]